Acute Myeloid Leukemia: Evolving Perspectives on Testing, Targeted Therapies, and Transplantation

EP. 1: Role of Molecular Testing in AML

January 15th 2021

EP. 2: Molecular Testing in Community Practices

January 15th 2021

EP. 3: FLT3 Testing for Treatment of AML

January 21st 2021

EP. 4: Prognostic Significance of IDH Mutations in AML

January 21st 2021

EP. 5: Assessing MRD Status in AML

January 25th 2021

EP. 6: MRD Monitoring in FLT3 ITD AML

January 25th 2021

EP. 7: Role of FLT3 Inhibitors in Chemo-Ineligible AML

February 1st 2021

EP. 8: Management of AML: FLT3 Inhibitors and BCL2 Inhibitors

February 1st 2021

EP. 9: Sequencing of FLT3 Inhibitors in AML

February 8th 2021

EP. 10: Role of Dual Targeted Therapy in AML

February 8th 2021

EP. 11: Type 1/2 FLT3 Inhibitors in AML

February 15th 2021

EP. 12: BCL2 Inhibition in AML: VIALE-A Study

February 15th 2021

EP. 13: IDH1/2-Mutated Treatment-Naïve AML

February 22nd 2021

EP. 14: Novel Targets and Biomarkers in AML

February 22nd 2021

EP. 15: BMT CTN 1102 Study in High-Risk MDS

March 1st 2021

EP. 16: Use of Omidubicel Therapy in Hematologic Malignancies

March 1st 2021

EP. 17: Role of Transplant in AML

March 8th 2021

EP. 18: Use of APR-246 and Oral HMAs in AML

March 8th 2021

EP. 19: Maintenance Therapy Post-Transplant in AML

March 15th 2021

Patient selection for maintenance therapy post-allogeneic transplant in myeloid malignancies and thoughts on treatment of FLT3-mutated disease post-transplant with agents such as midostaurin.

EP. 20: Future Treatment Landscape of AML

March 15th 2021

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.